At least two million doses of long-acting cabotegravir for PrEP to be made available in 2025-2026 to meet growing demand where HIV burden and unmet need are greatestStrong progress made with generic ...

Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that Paolo ...

Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab) Cambridge, UK – 10 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral ...

EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the continued growth of its European footprint with a new office in Berlin, Germany, Europe’s ...

The annual conference will be attended by Team ViroCell, including its newly appointed VP of Corporate Development and Strategy, Nicholas Ostrout PhD London, UK, New York, US, 7 October 2024 – ...

A redefining rebrand for CRO Antibody Analytics as it announces plans for future growth7th October 24 - RoukenBio, the Collaborative Research Organisation (CRO) formerly known as Antibody Analytics, ...

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck ...

Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, ...

Major shareholder announcement for Genmab A/SCOPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Baillie ...